OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ott Discusses Ipilimumab and Nivolumab in Melanoma

January 2nd 2018

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.

Dr. Andreadis on CAR T-Cell Therapy for Pediatric ALL

December 29th 2017

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of chimeric antigen receptor (CAR) T-cell therapy for pediatric patients with acute lymphocytic leukemia (ALL).

Dr. Agarwal on the CheckMate-214 Trial for Kidney Cancer

December 29th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the CheckMate-214 trial for patients with kidney cancer.

Dr. Mahantsetty on Unmet Needs in Cervical Cancer

December 29th 2017

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, India, discusses unmet needs for patients with cervical cancer.

Dr. Levy on the Treatment of T790M-Mutant Lung Cancer

December 29th 2017

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.

Experts Reflect on Oncology Advancements in 2017

December 29th 2017

Key opinion leaders share the biggest advancements in oncology made this past year.

Dr. McDermott on Immunotherapy as a Standard of Care in RCC

December 28th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).

Dr. Reckamp on Molecular Testing in Lung Cancer

December 28th 2017

Karen Reckamp, MD, MS, medical oncologist, City of Hope, discusses the role of molecular testing for patients with lung cancer.

Dr. Hensley on Lynch Syndrome in Endometrial Cancer

December 28th 2017

Martee L. Hensley, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses Lynch syndrome for patients with endometrial cancer.

Dr. Agarwal on Androgen Receptor Inhibitors for Prostate Cancer

December 27th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Dr. Pal on the Mutational Burden in Bladder Cancer

December 27th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at City of Hope, discusses the mutational burden for patients with bladder cancer.

Dr. Ledermann on Systemic Treatment for Rare Gynecologic Tumors

December 27th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses systemic treatment for patients with rare gynecologic tumors.

Dr. Graff on the Role of Checkpoint Inhibitors in Prostate Cancer

December 27th 2017

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

Dr. Heinzerling on Stage III Treatment of NSCLC

December 26th 2017

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the treatment of patients with stage III non-small cell lung cancer (NSCLC).

Dr. Voss on the Future of Clinical Trials for Kidney Cancer

December 26th 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

Dr. Atkinson Discusses BRAF-Mutant Metastatic Melanoma

December 22nd 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses the treatment landscape for patients with BRAF-mutant metastatic melanoma.

Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL

December 22nd 2017

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).

Dr. Marshall Discusses Frontline Treatment for CRC

December 22nd 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

Dr. Wang Discusses Acalabrutinib in MCL

December 22nd 2017

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.

Dr. Cohen on Immunotherapy Combinations in Head and Neck Cancer

December 22nd 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.